NANTKWEST INC. DL-,0001 Forum: Community User: Ibt2

NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that Dr. Patrick Soon-Shiong and Company management will be participating in the Jefferies 2019 Annual Healthcare Conference being held in New York City from June 4th-7th, 2019. The presentations and one-on-one discussions will feature a science/medicine review, along with a clinical update provided by Dr. Soon-Shiong and Company management.

Brink Biologics Announces Research License Agreement with Worcester Polytechnic Institute for Use of NantKwest’s NK-92® Cells by Jen Hodson | May 1, 2019 | Press Releases NK-92® Cell Based Bioanalytical Solutions are the Key to Optimizing R&D and Commercial Product Development Efforts for Monoclonal Antibodies, Bi-Specifics and Related Biological Products SAN DIEGO–May 1, 2019- Brink Biologics, Inc., a NantKwest, Inc. (Nasdaq:NK) affiliate who serves as exclusively-licensed distributor of NantKwest’s proprietary NK-92® natural killer cells, offers a variety of research grade aNK™ and haNK® cell lines for non-clinical laboratory use in discovery, translational and developmental research and lot release testing for commercial products ranging from monoclonal antibodies, bi-specific biologics, cytokines and other bioactive products. Using living cells for functional assays such as ADCC, ADCVI and Cytokine Release Assays approximates closely what one would see in live animal models. Through the use of NK-92® natural killer cells in these assays, assay variability and unreliability are minimized. For this reason, NK-92® cells are rapidly becoming the preferred next-generation bioanalytical testing solution among large pharma commercial developers, biosimilar developers, medical research institutions, universities and the global research community. Through a limited arrangement, Brink Biologics is pleased to announce that the company has non-exclusively licensed its next generation bioanalytical testing solution to Worcester Polytechnic Institute (WPI). The terms of the agreement are not disclosed. Jeannine Coburn, PhD, assistant professor of biomedical engineering at Worcester Polytechnic Institute, will use the cells in her research into the development of clinically translatable drug delivery strategies and three-dimensional in vitro human disease models using biologically-derived biomaterials. “This agreement demonstrates the respect that research institutions have for NantKwest’s proprietary rights in its innovative cell lines and foundational technologies. Every laboratory should get its NK-92® cells from Brink Biologics, which is the only licensed commercial and research distributor of genuine NK-92®,” said Mark Kokes, Chief Intellectual Property Officer of NantWorks, LLC, supporting Brink Biologics and NantKwest. Patrick Soon-Shiong, MD, Chairman and CEO of NantKwest added, “With over 200 publications citing the use of NantKwest’s NK-92® cells, the unique, enabling and proprietary characteristics of these novel natural killer cells are well established. NK-92® cell-supported assays have become the trusted and increasingly popular choice of large pharma and biotech companies for their growing antibody development programs and commercial product release testing.” Dr. Soon-Shiong continued, “These novel and proprietary cells form the foundation for NantKwest’s clinical-stage aNK™, haNK®, and t-haNK™ natural killer cell-based therapeutics programs and, through Brink Biologics’ offering, they also represent a unique, next generation bioanalytical testing solution. We are therefore very pleased to announce this license agreement with Worcester Polytechnic Institute.” About Brink Biologics Brink Biologics, Inc. (BBI) is a NantKwest, Inc. (NASDAQ: NK) affiliated next-generation bioanalytical testing solutions company located in the prestigious Torrey Pines biotechnology science park in San Diego, CA. NK-92® cells, aNK™ and haNK® cells are natural killer cell lines originating from a singular source, established in stable cultures under GLP & cGMP conditions and further modified and assembled into distinct panels of cell-lines, suitable for a range of laboratory testing applications. These Neukopanel® Cell Lines include CD16 expressing NK-92® cell lines, providing for the first time the means to establish a consistent, robust, and reliable assay for assessment of ADCC activity. NEUKOPANEL is a trademark of Brink Biologics, Inc. For additional information and licensing inquiries, please visit www.brinkbiologics.com.

https://seekingalpha.com/article/4253852-nantkwest-still-going-cancer-moonshot

CULVER CITY, Calif.--(BUSINESS WIRE)--Mar. 25, 2019-- NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that Patrick Soon-Shiong, MD, the company’s Chairman & CEO, on March 21, 2019, exercised 17,589,250 warrants with an exercise price of $1.9984 and 1,851,000 options with an exercise price of $2.1983, representing an aggregate cash exercise price of $39.2 million. In commenting on the exercise of the warrants and options, Dr. Soon-Shiong said the following: “Since the launch of NantKwest in 2015, the company has *** remarkable progress in the development of a true, 'off-the-shelf' and 'ready-to-use' Natural Killer (NK) cell therapy that could be shipped on an 'as needed basis,' just about anywhere in the world. We have successfully established a truly off-the-shelf, cryopreserved product and are now ready to embark on pivotal trials. This advanced manufacturing capability combined with our ability to develop NK cells with high killing activity provides us with a distinct advantage as the leading company developing an immediately available NK cell therapy for patients with cancer.” Dr. Soon-Shiong continued, “My commitment and confidence in the future success of NantKwest has never been stronger. I firmly believe that the natural killer cell represents the missing link in our war against cancer. I believe that only by orchestrating the activity of the natural killer cell, the innate immune system, as well as the killer T cell, the adaptive immune system, could we achieve long lasting responses to immunotherapy. NantKwest represents this next generation of cell therapy with the potential to achieve activation of the memory T and NK cell, the holy grail of immunotherapy. Contributing an additional $39.2 million to the financial resources of NantKwest will enable the rapid opening of multiple clinical trial sites for the Phase 2 trial of off-the-shelf activated natural killer cells (haNK cells), combined with an IL-15 cytokine (N-803) which may proliferate NK and T cells, to treat refractory patients suffering from a deadly disease, Merkel Cell Carcinoma. In addition, preclinical data of the world’s first targeted off-the-shelf haNK cells (t-haNK) are highly encouraging and we are planning the first in human trials of both PD-L1 t-haNK and CD-19 t-haNK (targeted-haNKs) this year.” Dr. Soon-Shiong provided an update on the haNK and t-haNK programs at his keynote address to the scientific community at "The Innate Killer Summit" in San Diego on March 20, 2019.

Mit dem Geld ist die Forschung erstmal sichergestellt

Gailooooooooooo, Glückwunsch Moma 👍👍👍

NantKwest and ProMab Biotechnologies are collaborating to develop a novel immunotherapy for multiple myeloma using natural killer (NK) cells that target the B-cell maturation antigen, or BCMA. The therapy, called chimeric antigen receptor (CAR) NK-cell, is a tweaked version of the conventional CAR-T cell therapy: instead of isolating T-cells from a patient or donor’s blood, researchers isolate NK cells. The cells are then modified in the lab to recognize cancer cells more effectively before being infused back into the patient. In this case, the NK cells will be modified to target BCMA, a cell surface protein produced at high levels by several cancer cell types, including multiple myeloma and other B-cell malignancies. “With an estimated five-year survival rate of around 49% and accounting for 10% of all hematological malignancies, patients with multiple myeloma are in critical need for more effective treatment options,” Patrick Soon-Shiong, CEO of NantKwest, said in a press release. NK cells, like T-cells, are an integral part of the body’s immune system and play a major role in protecting against cancer. An advantage over T-cells is that they have intrinsic anti-tumor activity and do not need to be activated to target cancer cells. Also, they don’t need to be matched to a specific patient. According to recent studies, CAR NK cells could be safer, faster to produce, and cheaper, and they may work in situations where T-cells fail. “We are pleased to announce this collaboration with ProMab Biotechnologies, marking another milestone for NantKwest in the development of targeted, next generation, NK cell therapeutics against multiple myeloma and other cancers,” said Soon-Shiong. “We believe NantKwest’s CAR-based NK cell therapy may represent a much needed new treatment option for these patients. We eagerly anticipate growing our relationship with ProMab and accelerate the development of these new and innovative, next-generation off-the shelf, CAR-based NK cell therapies,” he added. In addition to BCMA, the new collaboration includes an option to develop up to five additional NK-targeting sequences. “This new partnership allows NantKwest to leverage the breadth of our monoclonal antibody generation and validation platform, our human antibody library screening capabilities, together with NantKwest’s strong NK cell engineering, manufacturing, and clinical expertise,” said John Wu, president and CEO of ProMab Biotechnologies. “We look forward to working together with the NantKwest team to more rapidly bring new NK cell therapeutics into the clinic.”

Ohne News ein Ding der Unmöglichkeit

Rebound bis 3 usd?

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. JPMorgan Chase & Co. lifted its holdings in shares of Nantkwest by 132.8% during the third quarter. JPMorgan Chase & Co. now owns 111,641 shares of the biotechnology company’s stock worth $413,000 after buying an additional 63,689 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Nantkwest by 40.5% during the second quarter. Bank of New York Mellon Corp now owns 170,271 shares of the biotechnology company’s stock worth $521,000 after buying an additional 49,040 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Nantkwest by 27.9% during the second quarter. Millennium Management LLC now owns 200,430 shares of the biotechnology company’s stock worth $613,000 after buying an additional 43,686 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Nantkwest by 72.2% during the second quarter. Renaissance Technologies LLC now owns 520,400 shares of the biotechnology company’s stock worth $1,592,000 after buying an additional 218,200 shares during the last quarter. Hedge funds and other institutional investors own 13.58% of the company’s stock.

Director Steve Gorlin hat die letzten Wochen Aktien im Wert von round about 850K Dollar verkauft. Der ahnt wohl schon was kommt...

Im Rahmen unseres NK-Zelltherapieprogramms der nächsten Generation haben wir die potenzielle Targeting- und Homing-Effizienz der haNK-Zelltherapie weiter verbessert, indem wir sowohl ein CD19-Targeting-CAR als auch den Chemokin-Homing-Rezeptor CC Chemokine Receptor Type 7 (CCR7) einbauen. , die sowohl auf den Chemokin (CC-Motiv) -Liganden CCL19 (CCL19) als auch auf den Chemokine (CC-Motiv) -Ligand 21 (CCL21) abzielen, wichtige Signalmoleküle, die in Lymphknoten exprimiert werden, um das Homing zu diesen Geweben zu steuern. Diese Tri-Targeting-NK-Zelltherapie zielt darauf ab, die NK-Zellaktivität durch Erhöhen der NK-Zellmigration zu den Tumorstellen zu maximieren und die Krebszellabtötungsaktivität durch sowohl CD19-zielgerichtete CAR-vermittelte Tötung als auch die durch Antikörper vermittelte Tötung in Kombination mit monoklonalen klonalen Antikörpern zu erhöhen wie Rituximab.

NantKwest to Present Updated Preclinical Data at the 60th Annual Meeting of the American Society of Hematology Novel Trisprcific CD19.t-haNKTM Natural Killer Cell Therapy Engineered for Enhanced Tumor Homing for B Cell Lymphoma December 03, 2018 11:00 AM Eastern Standard Time CULVER CITY, Calif.--(BUSINESS WIRE)--NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, today announced an abstract/poster presentations will be given at the upcoming 60th Annual Meeting of the American Society of Hematology (ASH) in San Diego, CA, which runs from December 1-4, 2018. Presentation Title: Providing a Homing Receptor for CAR Engineered NK Cells - Improving Cellular Immunotherapy for B-Cell Lymphoma Abstract: #4547 Presenter: Nathan Thomas Schomer, Laurent Boissel, Karen Jiang, Hans Klingemann, John Lee, and Patrick Soon-Shiong, NantKwest, Inc., Culver City, CA Date: Monday, December 3, 2018, 6:00-8:00pm Location: San Diego Convention Center, Hall GH Presentation Highlights NantKwest’s proprietary natural killer (NK) therapy is based on an activated natural killer cell platform (aNK) derived from a novel cell line with potent cytotoxicity. With over 400 doses safely administered to over 80 patients across multiple Phase I/II clinical trials, NantKwest’s off-the-shelf therapies have demonstrated encouraging clinical responses across a broad range of cancer cell types.

Die Überlebensrate in Monaten ist aber schwer zu vergleichen, die Patienten überlebten 9,5 Monate im dritten Stadium gegenüber 8,7 Monate von Patienten im ersten Stadium. Ganz schlecht ist das also nicht aber mehr versprochen habe ich mir schon

Bahnbrechend ist das aber noch keineswegs